Abstract 247P
Background
Adenocarcinoma is an uncommon histologic variant and accounts for 0.5-2% of bladder cancers in the United States. Due to its rarity, there is limited data in the literature specifically focused on bladder adenocarcinoma treatment. So, the aim of this study is focused on evaluating the impact of chemoradiotherapy compared to multiple treatment modalities on the survival of patients with primary bladder adenocarcinoma.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Program 17 registries database was utilized to identify primary bladder adenocarcinoma cases from (2000-2020). The disease stages and sociodemographic data were collected. The patients were subgrouped according to the treatment modality: primary chemotherapy, surgery only, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant chemoradiotherapy. SPSS Version 23 was used for data analysis. log-rank Kaplan-Meir curve was used for survival analysis.
Results
A total of 2500 cases of bladder adenocarcinoma were identified. Overall, the 5-year relative survival was 43.1%. With multiple treatment options, we found surgery with no systemic therapy had a better survival outcome (47.4%) compared to adjuvant chemotherapy (38%), adjuvant chemoradiotherapy (31.4), adjuvant radiotherapy (21.5%), and least primary chemotherapy (4.9%) (P <0.001). In the group that had surgical management with no systemic therapy, the localized stage had significantly improved survival compared to the regional and distant spread (62%, 40%, and 10.8%, respectively; P <0.001).
Conclusions
This study provides a comprehensive evaluation of multiple treatment modalities, and the results highlight surgery with no systemic therapy as the modality of choice for improved survival outcome. This eliminates the burden of adjuvant therapy with unfavorable side effects. However, few selected patients may use chemo(radio)therapy with special considerations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract